Annotation Detail
Information
- Associated Genes
- CDKN2A
- Associated Variants
-
CDKN2A p16 EXPRESSION
CDKN2A p16 EXPRESSION - Associated Disease
- head and neck squamous cell carcinoma
- Source Database
- CIViC Evidence
- Description
- In this retrospective analysis of p16 status as surrogate marker for HPV in the SPECTRUM trial, p16 (CDKN2A) expression was not associated with improved response to EGFR-directed therapy (Panitumumab) in combination with chemotherapy compared to chemotherapy alone.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/696
- Gene URL
- https://civic.genome.wustl.edu/links/genes/14
- Variant URL
- https://civic.genome.wustl.edu/links/variants/272
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Head And Neck Squamous Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Panitumumab
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 23746666
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Panitumumab | Resitance or Non-Reponse | true |